Weight loss

Seed fund
#Funding #Obesity #Seed funding #Start-ups #University of Michigan #Weight loss

Weight loss start-up secures $7.8m investment

University of Michigan (U-M) spinout company Courage Therapeutics has received a seed investment of up to $7.8 million from Arsenal Bridge Ventures.  The investment will enable Courage Therapeutics to complete essential testing and development to advance its drug candidates to clinical trials.   The company’s two drug development programmes aim to… Read More

#Business & Investment #News #Start-up Zone

#Diabetes #Liver disease #Metabolic diseases #Obesity #Weight loss

This week in drug discovery (19-23 May) 

News round-up for 19-23 May by DDW Senior Digital Content Editor Diana Spencer. Our news highlights this week focus on drug discovery for metabolic diseases, with a number of developments in treatments for obesity, liver disease, and diabetes. The top stories: GSK buys… Read More

#News

#Arecor Therapeutics #Collaboration #Obesity #Skye Bioscience #Weight loss

Partners develop enhanced formulation of obesity candidate

Arecor Therapeutics and Skye Bioscience have agreed a formulation development collaboration to develop a novel, higher concentration formulation of Skye’s CB1 inhibitor, nimacimab.  Skye is evaluating nimacimab, a first-in-class CB1-inhibiting monoclonal antibody, in its Phase IIa CBeyond clinical trial in patients with obesity and overweight. Data from the initial 26-week… Read More

#Business & Investment #News

#MitoRX Therapeutics #Obesity #Preclinical investigations #Weight loss

Weight loss with muscle preservation for novel drug

MitoRx Therapeutics has shared results for its novel small molecule Myo4 targeting obesity at the 32nd European Congress on Obesity.  In the diet induced obesity (DIO) mouse model, Myo4 reduced weight while preserving muscle and bone mineral content.  The effect was seen with… Read More

#News

Obese man measures his waist
#GLP-1 #MetaVia #Obesity #Phase I trial #Weight loss

New obesity drug shows superior tolerability to GLP-1 agonists

MetaVia has announced positive results from the four-week multiple ascending dose (MAD) Part 2 of its Phase I clinical trial of DA-1726 for the treatment of obesity.  DA-1726 is a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor… Read More

#Editor's Choice #News

Pfizer, New York
#Clinical trial #GLP-1 #Pfizer #Weight loss

Pfizer discontinues oral GLP-1 receptor agonist danuglipron

Pfizer has announced its decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist, due to drug-induced liver injury.  Danuglipron (PF-06882961) was being investigated for chronic weight management.  The company’s dose-optimisation studies of once-daily formulations of danuglipron met key pharmacokinetic objectives and confirmed a formulation and dose… Read More

#Business & Investment #News #Trending News

Heart monitor
#Cardiovascular disease #Chronic kidney disease (CKD) #Diabetes #GLP-1 #Novo Nordisk #Weight loss

Oral semaglutide reduces risk of cardiovascular events

The results of the SOUL cardiovascular outcomes trial have demonstrated that Rybelsus (oral semaglutide) significantly reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD).   The new data were featured during a late-breaking clinical… Read More

#News

#GLP-1 #Weight loss #Women's health

New DDW Highlights podcast: 31 March 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Weight loss drugs have been… Read More

#News

#GLP-1 #Obesity #Weight loss #Women's health

This week in drug discovery (24-28 March) 

News round-up for 24-28 March by DDW Senior Digital Content Editor Diana Spencer. Weight loss drugs have been making the news this week. As we come to the end of Women’s History Month, two of the reported studies focus on women’s health, specifically the role of weight loss… Read More

#News

#Helicore Biopharma #Monoclonal antibodies #Obesity #Phase I trial #Weight loss

First-in-class GIP antagonist for obesity enters Phase I trials

Helicore Biopharma has reported dosing the first participant in its Phase I study of HCR-188 for the treatment of obesity.   HCR-188 is a first-in-class monoclonal antibody (mAb) designed to bind to circulating glucose-dependent insulinotropic peptide (GIP) ligand, unlike antibodies that bind the GIP receptor (GIP… Read More

#News

Patient injects Ozempic
#Gender #GLP-1 #Obesity #Olio Labs #Preclinical investigations #Weight loss

Study reveals insights into GLP-1 drug effectiveness across sexes 

A new study has uncovered fundamental sex-based differences in how weight loss medications interact with human biology, revealing why women experience more severe side effects from GLP-1 drugs such as Ozempic and Zepbound.  Founded by leading neuroscientists and computational biologists in 2023, Olio Labs uses a novel… Read More

#News

Endometriosis
#Endometriosis #GLP-1 #Weight loss

Mounjaro’s role in managing endometriosis

Endometriosis is a chronic and often debilitating condition affecting one in 10 women in the UK. Weight management and metabolic health play an essential role in symptom control. The weight loss drug Mounjaro (tirzepatide) and its effects on appetite regulation, insulin sensitivity, and weight loss, could be an unexpected tool… Read More

#News

Woman standing on scales
#Diabetes #GLP-1 #Obesity #Phase I trial #Vivani Medical #Weight loss

GLP-1 implant NPM-115 enters clinical trials for obesity

Vivani Medical has announced the successful administration of its first GLP-1 (exenatide) implant in the LIBERATE-1 clinical trial.   The company hopes to address one of healthcare’s most pressing challenges: medication adherence in metabolic diseases including chronic weight management and type 2 diabetes.   Vivani also announced… Read More

#News

Weight loss concept
#Clinical trial #Obesity #Oxford Medical Products #Weight loss

New generation in weight-loss therapies targets overweight

Oxford Medical Products (OMP) has announced additional three-month clinical trial results for Sirona, its weight-loss treatment targeting people who are overweight or have class I obesity (BMI 25-35) and those transitioning off GLP-1 medication.   The clinical trial took place across three NHS hospitals in the UK and… Read More

#News

#Artificial intelligence (AI) #Drug discovery #Molecular research #Ozempic #Stanford University #Weight loss

AI-enabled molecule discovery rivals Ozempic in weight loss

A naturally occurring molecule identified by Stanford Medicine researchers appears similar to semaglutide — also known as Ozempic — in suppressing appetite and reducing body weight. Notably, testing in animals also showed that it worked without some of Ozempic’s side effects such as nausea, constipation and significant loss of muscle… Read More

#News

#GLP-1 #Market reporting #Novo Nordisk #Obesity #Scandinavia #Weight loss

What effect have weight loss drugs had on the Scandinavian economy?

In less than a decade GLP-1 receptor agonists have transformed the treatment of obesity and made Novo Nordisk Europe’s most valuable company. Diana Spencer explores the current impact and potential future for these drugs. Originally designed in Scandinavia as a maintenance therapy for type 2 diabetes, GLP-1 receptor agonists are… Read More

#Exclusive Content #Market Reports #Trends & Analysis